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Objective: Bisphosphonates are considered potential disease modifying osteoarthritis (OA) agents. The
present study investigated the efﬁcacy of pre-emptive, early, and delayed alendronate (ALN) treatment
initiation on subchondral trabecular bone and cartilage in low-dose monosodium iodoacetate (MIA)-
induced knee OA in rats.
Methods:Male rats received pre-emptive (n¼ 12, day 0eend ofweek2), early (n¼ 12, end ofweek2eendof
week 6), or delayed (n¼ 12, end of week 6eend of week 10) ALN treatment (30 mg/kg/week). Pre-emptive
ALN-treated rats were scanned using in vivo micro-computed tomography (micro-CT) after 2 weeks and
then sacriﬁced, early ALN-treated rats were scanned after 2 and 6 weeks and sacriﬁced, and the delayed
ALN-treated rats were scanned after 2, 6, and 10weeks of OA induction and sacriﬁced. After sacriﬁce, bone
histomorphometry and histology of the tibia and biomarker analyses were undertaken. Changes in hind
limb weight-bearing were assessed from day 1 until day 14.
Results: MIA-induced pathological features similar to progressive human OA in the cartilage and sub-
chondral bone. Pre-emptive ALN treatment preserved subchondral trabecular bone microarchitecture,
prevented bone loss, decreased bone turnover and joint discomfort. Pre-emptive ALN treatment had
moderate effects on cartilage degradation. Early and delayed ALN treatments prevented loss of trabeculae
and decreased bone turnover, but had no signiﬁcant effect on cartilage degradation.
Conclusion: ALN prevented increased bone turnover and preserved the structural integrity of subchondral
bone in experimental OA. The time point of treatment initiation is crucial for treating OA. Treating both
the subchondral bone and cartilage in OA would be clinically more beneﬁcial.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is characterised mainly by loss of articular
cartilage and altered subchondral bone remodelling1. Numerous
important transformations occur in the subchondral bone during
the initiation and progression of OA, such as increased subchondral: G. Mohan, Bone and Joint





s Research Society International. Pbone remodelling2, leading to hypomineralisation with greater
amounts of osteoid, and reduced mechanical properties3. Repeated
loading of the subchondral bone with altered chemical and me-
chanical properties results in the progression of OA4. Despite the
explosion of information regarding OA pathology, the mechanism
of OA initiation and progression remains incompletely understood
and currently there is no cure for OA.
Bisphosphonatesarepotent inhibitors of bone resorptionandbone
turnover. Clinically, bisphosphonates are used in the treatment of
osteoporosis, Paget’s disease, hypercalcaemia, andmetastatic cancer5.
Recent pre-clinical studies and clinical trials have shown that
bisphosphonates could be used as potential disease modifying OA
drugs due to their ability to suppress increased bone turnover.ublished by Elsevier Ltd. All rights reserved.
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clinical trials, alendronate (ALN), a potent nitrogen containing bisphos
phonate, has been shown to prevent subchondral bone lesions and
reduce knee pain; however, it did not prevent progression of OA9. In
another study, ALN decreased spinal osteophyte progression in
women with vertebral fractures, despite it not showing a signiﬁcant
improvement in spinal disc space narrowing10. However, in those
human OA studies, efﬁcacy of ALN was assessed with the treatment
mostly initiated at advanced stages of OA. On the other hand, in pre-
clinical studies, ALN treatment initiated either from a few days
before OA induction or from the day of OA induction, has been shown
to protect cartilage and inhibit altered bone remodelling11e14.
Previously, we have demonstrated that a low-dose (0.2 mg)
monosodium iodoacetate (MIA)-induced OA rat model mimics
important pathologic features of progressive human OA in a timely
manner15. This OA rat model is suitable for monitoring disease
progression using in vivo 3D micro-computed tomography (micro-
CT). In a study using high-dose (1 mg) MIA-induced OA rat model, it
has been shown that pre-emptive zoledronate treatment prevented
decrease of subchondral bone mineral density (BMD), whereas
delayed treatment reduced its efﬁcacy16. That study assessed BMD
by using dual energy X-ray absorptiometry, which gives bone
quantity measures from planar projections of the underlying three-
dimensional (3D) bone structure. However, the effect of
bisphosphonate treatment on subchondral trabecular bone micro-
architecture in the MIA-induced OA rat model in particular, with
treatment initiated at different stages of the disease, has not yet
been investigated using 3Dmethods in vivo, such as high-resolution
in vivo micro-CT. It is important to investigate the effect of the time
point (pre-emptive, early, and delayed) of bisphosphonate-treat-
ment initiation on the subchondral trabecular bone micro-
architecture, which plays an important role in determining bone
strength17,18. Moreover, in vivo micro-CT has the added advantage
for monitoring disease progression in the same animal over time.
The purpose of this study was to use the low-dose MIA-induced
OA rat model to test the hypothesis that the efﬁcacy of ALN on
subchondral 3D microarchitecture decreases with delayed treat-
ment, using in vivo micro-CT. We also assessed the efﬁcacy of ALN
on cartilage and subchondral trabecular bone turnover, and joint
discomfort in this animal model at different time points of treat-
ment initiation.
Materials and methods
Animals and OA induction
Eighty-four 8-week-old male Wistar ratsz230 g (ARC, Canning
Vale, WA, Australia), were kept in a sanitary ventilated animal room
(12-h lightedark cycle) with food andwater available ad libitum. The
rats were divided into three groups: OA (n ¼ 36), ALN (n ¼ 36), and
control (n ¼ 12). On day 0, all the rats were anaesthetized with iso-
ﬂurane and OAwas induced (OA and ALN group) by injecting 0.2 mg
MIA in the rat’s right knee joint as described previously15. The left
contralateral control knee was injected with sterile saline. The con-
trol rats received a single sterile saline injection in the right knee.
ALN treatment
ALN was administered as twice-weekly subcutaneous injections
at a dosage of 15 mg/kg. The ALN solution was made by dissolving
one tablet of ALN sodium (Fosamax 40 mg, MSD, South Granville,
NSW, Australia) in 100 ml of sterile water and then diluted with
sterile physiologic saline to appropriate concentrations to obtain
the required dose as above. The ALN treatment regime was as
follows:1. Pre-emptive ALN treatment e from day 0 to end of week 2.
2. Early ALN treatment e from end of week 2 (day 14) to end of
week 6.
3. Delayed ALN treatmente from end of week 6 (day 42) to end of
week 10.
The hind limbs of all the rats were imaged with high-resolution
in vivo micro-CT. The ﬁrst subgroup of rats from the OA (n ¼ 12),
pre-emptive ALN treatment (n ¼ 12) and control groups (n ¼ 4)
were scanned after 2 weeks and sacriﬁced. The second subgroup of
rats from the OA (n ¼ 12), early ALN treatment (n ¼ 12) and control
groups (n ¼ 4) were scanned after 2 and 6 weeks, and sacriﬁced.
The third subgroup of rats from the OA (n ¼ 12), delayed ALN
treatment (n¼ 12) and control groups (n¼ 4) were scanned after 2,
6, and 10 weeks, and sacriﬁced.
Double-ﬂuorescent labelling of newly formed bone was ach-
ieved by intraperitoneal injections of calcein and xylenol orange
(5 mg/kg, 90 mg/kg body weight respectively; SigmaeAldrich,
Sydney, NSW, Australia), 7 and 2 days before sacriﬁce. All pro-
cedures were approved by The University of Adelaide Animal Ethics
Committee and The Institute of Medical and Veterinary Science
Animal Ethics Committee.
In vivo micro-CT analysis
In vivo micro-CT imaging was performed using a Skyscan 1076
(Skyscan, Kontich, Belgium) as described previously15,19. Brieﬂy,
each rat was anaesthetized with isoﬂurane and the right and left
knees (scanning ﬁeld of view centred on the proximal tibia) were
scanned separately using the following scanner settings: X-ray
source voltage 60 kVp, current 100 mA, a 1-mm thick aluminum
ﬁlter, 1 frame averaging, 8.7 mm pixel size, 4.7 s of exposure time,
and a rotation step was 0.8, with rotation over 19715,19. Each scan
lasted for 20 min during which the rat was under isoﬂurane
anaesthesia. The cross-sectional images were reconstructed using a
ﬁltered back-projection algorithm (NRecon, V 1.4.4, Skyscan, Kon-
tich, Belgium).
On the stack of reconstructed micro-CT cross-section images,
manual regions of interest (ROIs) were drawn in the sub-
chondral trabecular bone for the medial and lateral tibial
plateau, for both the right and left knees (software CT Analyser,
V 1.8.05, Skyscan, Kontich, Belgium)15. The volume of interest
(VOI) included the tibial subchondral trabecular bone (below
the subchondral plate, extending distally towards the growth
plate) excluding both the cortical bone and growth plate inter-
face. The following 3D morphometric parameters were calcu-
lated for the medial, lateral, and total (¼medial þ lateral) VOI of
subchondral trabecular bone (software CT Analyser, Skyscan):
bone volume (BV), bone volume fraction (BV/TV), trabecular
thickness (Tb.Th), trabecular separation (Tb.Sp) and trabecular
number (Tb.N).
Hind limb weight-bearing (HLWB) assessment
HLWB of the rats from the control, OA and early ALN groups was
measured using an incapacitance tester (Bioseb, Chaville, France).
The percentage weight borne on the MIA-injected limbwas used as
an index of joint discomfort in OA20,21. Brieﬂy, the rats were posi-
tioned to stand on their hind paws in an angled (65 from hori-
zontal) plexiglass box placed above the incapacitance tester so that
each hind paw rested on a separate force plate. The force (g) exerted
by each limb was measured. Three consecutive 5-s readings were
taken and averaged to obtain the mean score20,21. The percent
weight borne on the MIA-injected limb was determined as
described by Pomonis et al.21
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After sacriﬁce at 2, 6, and 10 weeks, the tibiae (n ¼ 6 for each
subgroup within the OA and the ALN treatment group and n¼ 2 for
each subgroupwithin the control group) were dissected, ﬁxed in 4%
paraformaldehyde, decalciﬁed, and embedded in parafﬁn. Three
coronal sections (5 mm thick, 100 mm apart) were stained with
Safranin O/fast green22. The sections were observed for OA-like
features and the Osteoarthritis Research Society International
(OARSI) scoring method was used to grade and stage tibial
cartilage23.
The remaining tibiae (n¼ 6 for each subgroupwithin the OA and
the ALN treatment group and n ¼ 2 for each subgroup within the
control group) were ﬁxed in 70% ethanol, dehydrated through a
graded series of ethanol and embedded in methyl methacrylate.Fig. 1. Effect of pre-emptive ALN treatment on tibial subchondral trabecular bone after 2 w
knee from the OA and the ALN groups and the right knee of the control group are shown.
***P < 0.0001.The amount of label incorporation in the tibial subchondral
trabecular bone was measured in two unstained sections (5 mm
thick, 100 mm apart) under epi-ﬂuorescence and the mineral
apposition rate (MAR) was calculated as described by Frost.24
Serum COMP, CTX-I and urine CTX-II analysis
Fasting blood specimens were obtained from all the rats at
baseline, 2, 6, and 10 weeks after OA induction for repeated mea-
surement of serum cartilage oligomeric matrix protein (COMP e
cartilage turnover marker), and C-terminal telopeptide of collagen
type I (CTX-I e bone turnover marker). A morning spot urine
sample was collected from all the rats after 2, 6, and 10 weeks of OA
induction for urinary C-terminal telopeptide of collagen type II
(CTX-II e cartilage turnover marker) analysis. The samples wereeeks of ALN treatment initiation. Histomorphometric parameters of the MIA-injected
Results are reported as mean  95% conﬁdence intervals. *P < 0.05, **P < 0.001, and
G. Mohan et al. / Osteoarthritis and Cartilage 21 (2013) 1595e16041598collected and frozen in aliquots at 80C. Assays for serum COMP
(Animal COMP ELISA, MD Bioproducts, St. Paul, MN, USA), CTX-I
(IDS RatLaps ELISA, Fountain Hills, AZ, USA) and urinary CTX-II
(IDS Urine pre-clinical Cartilaps ELISA kit, Fountain Hills, AZ, USA)
were performed according to the manufacturers’ instructions. Each
measurement for urinary CTX-II was normalized to urinary
creatinine.
Statistical analysis
For histomorphometric parameters repeated measures two-way
analysis of variance (ANOVA) was applied to determine the “time
effect” and “time by group interaction effect”. If F-values for a given
variable were found to be signiﬁcant, a paired t-test was applied, to
assess the changes between theMIA-injected knee and contralateralFig. 2. Effect of early ALN treatment (started 2 weeks after OA induction) on tibial subchond
OA and the ALN groups and the right knee of the control group are shown. Results are repor
*P < 0.05, **P < 0.001, and ***P < 0.0001.control knee. The P-values were adjusted for repeated comparisons
byHolm’s Bonferroni stepdownprocedure25. A comparisonbetween
groups at each time point was performed using a one-way ANOVA
with Tukey’s post hoc test (SPSS for Windows, Rel. 19.0.0. 2010. Chi-
cago: SPSS Inc., USA). HLWB and biomarker data setswere examined
using KruskaleWallis test with Dunn’s multiple comparison test
(GraphPad Prism version 5.03 for Windows, San Diego, California,
USA). Differences were considered signiﬁcant for P < 0.05.
For OARSI score and MAR, the control group was not included
since statistical analysis could not be performed with n ¼ 2. The
OARSI and MAR values were analysed with a two-way ANOVA to
determine the “time effect” and “time by group interaction effect”.
If F-values were found to be signiﬁcant, a paired t-test was applied
and the P-values were adjusted for repeated comparisons by
Holm’s Bonferroni stepdown procedure.ral trabecular bone. Histomorphometric parameters of the MIA-injected knee from the
ted as mean  95% conﬁdence intervals. # Measurement after ALN treatment initiation.
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In vivo micro-CT: subchondral trabecular bone histomorphometry
Effect of pre-emptive ALN treatment
In theMIA-injected knee of the OA group, therewas a signiﬁcant
decrease in BV, BV/TV, and Tb.N, and a signiﬁcant increase in Tb.Sp,
relative to the control group (Fig. 1). Pre-emptive ALN treatment
effectively prevented the early subchondral bone loss and there
was a non-signiﬁcant increase in Tb.N compared to the OA group.
BV, BV/TV and Tb.N did not differ signiﬁcantly between the MIA-
injected knee of the pre-emptive ALN treatment group and the
control group. The Tb.Sp in the ALN group was signiﬁcantly lower
relative to the OA group, and signiﬁcantly higher relative to the
control group.Fig. 3. Effect of delayed ALN treatment (started 6 weeks after OA induction) on tibial subch
the OA and the ALN groups and the right knee of the control group are shown. Results ar
initiation. *P < 0.05, **P < 0.001, and ***P < 0.0001.Effect of early ALN treatment
After 6 weeks of OA induction, there was no signiﬁcant differ-
ence in BV and BV/TV in the MIA-injected knee of the OA group
relative to the control group (Fig. 2). However, Tb.Th and Tb.Sp
were signiﬁcantly increased; whereas, Tb.N was signiﬁcantly
decreased relative to the control group (all compartments). The
MIA-injected knee of the early ALN treatment group did not show
signiﬁcant differences in BV/TV and Tb.Th compared to the OA
group. However, BV was signiﬁcantly increased (medial compart-
ment), Tb.N was signiﬁcantly increased (all compartments), and
Tb.Sp was signiﬁcantly decreased (all compartments). Compared to
the control group, Tb.N and Tb.Sp from the MIA-injected knee in
the early ALN treatment group were not signiﬁcantly different
(Fig. 2); however, BV, BV/TV, and Tb.Th were signiﬁcantly
increased.ondral trabecular bone. Histomorphometric parameters of the MIA-injected knee from
e reported as mean  95% conﬁdence intervals. # Measurement after ALN treatment
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After 10 weeks (4 weeks after ALN treatment initiation), there
was no signiﬁcant difference in the histomorphometric parameters
in theMIA-injected knee (all compartments) between the OA group
and the ALN treatment group (Fig. 3). In the OA group relative to the
control group, Tb.N was signiﬁcantly decreased, whereas Tb.Th and
Tb.Sp were signiﬁcantly increased (all compartments). In the
delayed ALN treatment group compared to the control group, BV
(medial compartment), Tb.Th, and Tb.Sp (all compartments) were
signiﬁcantly increased. Tb.N was signiﬁcantly decreased compared
to the control group only in the lateral compartment.
Effect of ALN on HLWB
In the OA group, the HLWB of the MIA-injected limb was
signiﬁcantly decreased on day 1, 3, (P < 0.001 for both) 5, and 7
(P< 0.05 for both) compared to its baseline value on day1 (Fig. 4).
Compared to the control group, the OA group showed a trend to-
wards decreased weight-bearing on the MIA-injected limb from
day 1 to day 7, with signiﬁcant difference in HLWB between the OA
and control groups observed on day 3 (P < 0.05). Pre-emptive ALN
treatment signiﬁcantly prevented the decrease in weight-bearing
of the MIA-injected knee on day 1, 3, and 5 (P < 0.05, P < 0.001,
and P < 0.05, respectively, compared to the OA group). There was
no difference in HLWB between the ALN and the control groups at
any time point. There was no change in HLWB of rats in the ALN
group over time, similar to the control group.
Effect of ALN on microscopic cartilage changes
There were no OA-like microscopic cartilage changes in the
tibiae of the control group and in the contralateral control knees of
OA and ALN treatment groups, at any time point (Fig. 5). In theMIA-
injected knee of the OA group, after 2 weeks there was loss of
proteoglycan, mild chondrocyte degeneration, and cartilage ﬁbril-
lation in the tibial articular cartilage. Formation of small osteo-
phytes was evident in all the six rats. In the MIA-injected knee of
the pre-emptive ALN treatment group the proteoglycan loss and
chondrocyte degeneration were less severe compared to the OA
group and the cartilage was intact. Small osteophytes were present
in ﬁve out of six rats.Fig. 4. Effect of pre-emptive ALN treatment on rat HLWB. Pre-emptive ALN effectively
prevented decreased weight-bearing of the OA knee on day 1, 3 and 5 after MIA in-
jection. Results are reported as mean  95% conﬁdence intervals.
a ¼ HLWB difference over time compared to baseline value of the OA group (P < 0.001
for day 1 and 3 and P < 0.05 for day 5 and 7 respectively).
b ¼ OA vs control (P < 0.05). *P < 0.05 OA vs ALN, ***P < 0.001 OA vs ALN.After 6 weeks, the MIA-injected knee from both the OA and the
early ALN treatment groups showed loss of proteoglycans, branched
vertical ﬁssures with chondrocyte necrosis, chondrocyte cluster
formation, subchondral bone sclerosis and osteophyte formation.
However, in the early ALN treatment group the osteophyte was in
the form of cartilaginous outgrowths without bony transformation
(Fig. 5). After 10 weeks both the OA and the delayed ALN treatment
groups showed severe proteoglycans loss, chondrocyte necrosis,
chondrocyte clusters, extensive cartilage matrix loss, exposure of
sclerosed subchondral bone andmineralised osteophytes (Fig. 5). At
6 and 10 weeks, cysts were observed in four out of six rats in the OA
group and in three out of six rats in the delayed ALN treatment
group. In both the OA and ALN group subchondral bone, normal
haematopoietic bone marrow was replaced by ﬁne ﬁbrous stroma
containing spindle cells. The subchondral plate was breached in
focal areas with reparative tissue including ﬁbrocartilage.
The OARSI scores of the OA group were signiﬁcantly higher at 6
weeks (P < 0.001) and 10 weeks (P < 0.01) compared to 2 weeks
after MIA injection. Similarly, the OARSI scores of the early ALN
treatment and the delayed ALN treatment group were signiﬁcantly
higher compared to the pre-emptive ALN treatment group
(P < 0.001 and P < 0.05 respectively). The OARSI scores did not
differ between the OA group and the ALN treatment group at any
time point [Fig. 6(A)].
Effect of ALN on subchondral trabecular bone MAR
The MAR of the OA group was signiﬁcantly increased at 2 weeks
compared to 6 and 10 weeks in the medial (P < 0.0001, P < 0.01),
lateral (P ¼ 0.001, P < 0.01) and total (P < 0.0001, P < 0.001)
compartments. The MAR of the pre-emptive ALN treatment group
was signiﬁcantly increased compared to the early ALN treatment
and the delayed ALN treatment groups in all the three compart-
ments (P < 0.001 for all). Pre-emptive ALN treatment signiﬁcantly
decreased the MAR which was increased in the OA group at 2
weeks in the medial (P < 0.01), lateral (P < 0.01) and total
(P < 0.0001) compartments [Fig. 6(B)].
Effect of ALN on serum COMP, CTX-I and urine CTX-II
Figure 7 shows the levels of serum COMP, serum CTX-I and urine
CTX-II of the OA group, the ALN treatment group and the control
group, after 2, 6, and 10 weeks of OA induction. In all the three
groups there was statistically signiﬁcant decrease in the serum
COMP, CTX-I and urine CTX-II levels over time (P < 0.05). In the OA
group compared to the control group, there was a non-signiﬁcant
increase in serum COMP, CTX-I and CTX-II levels after 2, 6, and 10
weeks of OA induction. Pre-emptive ALN treatment, early ALN
treatment and delayed ALN treatment signiﬁcantly decreased the
serum CTX-I levels similar to the levels in the control group. In
contrast, ALN treatment (pre-emptive, early, and delayed) did not
have a signiﬁcant effect on serum COMP and urine CTX-II levels.
Discussion
Trabecular bone microarchitecture is an important determinant
of bone quality18, and changes in microarchitectural properties
have been reported previously in human OA26e28 and animal
studies29e31. In the present study, decreased BV and BV/TV was
observed after 2 weeks, followed by increased BV, BV/TV, Tb.Th,
Tb.Sp and reduced Tb.N at 6 and 10 weeks after OA induction. Pre-
emptive ALN treatment prevented subchondral trabecular bone
loss and preserved subchondral trabecular microarchitecture
(Suppl. Table 1). Early ALN treatment maintained subchondral Tb.N
and Tb.Sp (Suppl. Table 2), and delayed ALN treatment maintained
Tb.N (Suppl. Table 3). This suggests that pre-emptive ALN treatment
has the most beneﬁcial effect on subchondral trabecular bone
Fig. 5. Articular cartilage and subchondral boneofmedial tibial plateau fromcontrol, OA, andALN treatment groups after 2, 6, and10weeks (right tibia). Progressive cartilage degradation
wasevident in theOAgroup. Lossof trabeculaewasobservedafter 2weeks (square) followedbysubchondral bone sclerosis after6 and10weeks.Progressiveosteophyte formation (arrow)
was evident at 2, 6, and 10weeks after OA induction. In the pre-emptive ALN treatment group therewere less severe proteoglycan loss and less chondrocyte necrosis compared to theOA
group. Pre-emptive treatment did not have a signiﬁcant effect on the cartilage or osteophyte formation; however it prevented loss of subchondral trabeculae. Early ALN treatment
(treatment started 2 weeks after OA induction) and delayed ALN treatment (treatment started 6 weeks after OA induction) did not prevent cartilage degradation or subchondral bone
sclerosis. However, in the early ALN treatment group the osteophytes were in the form of cartilaginous outgrowths without bony transformation. Original magniﬁcation 40.
Fig. 6. (A) OARSI scores of OA, pre-emptive ALN, early ALN, and delayed ALN groups. ALN treatment did not have a signiﬁcant effect on OARSI score. Results are reported as
mean  95% conﬁdence intervals. (B) Tibial subchondral trabecular bone MAR of OA, pre-emptive, early ALN, and delayed ALN groups. In the OA group, MAR was signiﬁcantly
increased at 2 weeks compared to, 6 and 10 weeks after OA induction. Pre-emptive ALN treatment signiﬁcantly decreased MAR whereas; early ALN and delayed ALN treatment did
not have a signiﬁcant effect on MAR. Results are reported as mean  95% conﬁdence intervals. **P < 0.01.
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Fig. 7. Serum COMP, CTX-I, and urine CTX-II levels of the OA group, pre-emptive ALN, early ALN, delayed ALN treatment groups and control group. The pre-emptive, early, and
delayed ALN treatment did not have a signiﬁcant effect on serum COMP and urine CTX-II levels. However, they signiﬁcantly suppressed serum CTX-I levels observed in the OA group.
Results are reported as mean  95% conﬁdence intervals. *P < 0.05 and **P < 0.01.
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treatments (early and delayed ALN treatment). The present study,
demonstrates the time-dependency of the beneﬁcial effects of ALN
on the subchondral trabecular bonemicroarchitecture, using in vivo
micro-CT in a low-dose MIA rat model. A similar dependence on
time point of bisphosphonate-treatment initiation on bone
microarchitecture was observed in a postmenopausal rat model of
OA, with ovariectomized rats treated with ALN14, and in osteopo-
rosis studies, with ovariectomized rats treated with zoledronic
acid19,32. It is important to note that there was an increase in bone
histomorphometric parameters, and bone and cartilage turnover
rate over time due to normal growth of the rats. However, since all
the rats were of the same age and the OA group and control group
were compared against an age-matched control group of rats, the
results from our study were not confounded by the age of rats.In the present study, we did not observe signiﬁcant improve-
ment in cartilage degradation after 2 weeks of ALN treatment in the
pre-emptive ALN group. This could be due to the fact that not
enough time has elapsed to actually observe a beneﬁcial effect of
ALN on cartilage degradation. In our study, although ALN treatment
did not have a signiﬁcant effect on OARSI score, we observed less
severe loss of proteoglycans and chondrocytes in the pre-emptive
ALN group. This suggests that pre-emptive ALN treatment has a
moderate effect on cartilage degradation in this animal model.
Hayami et al. reported similar observations in a rat anterior cruciate
ligament transection (ACLT) model of OA in which a clinically
relevant dose of 30 mg/kg/week ALN completely inhibited the
early bone loss at 2 weeks but did not have a signiﬁcant effect
on cartilage degradation. However, they found that a high dose of
240 mg/kg/week ALN prevented bone loss and had partial
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rabbit ACLT model, Zhang et al. showed that 70 mg/kg/week ALN
treatment protected the cartilage and improved subchondral bone
architecture by preventing increased subchondral bone resorption
at the early phase of OA13.
A dosage of 30 mg/kg/week of ALNwas used in the present study.
At this dose, ALN has been shown to completely prevent bone
resorption in ovariectomized rats and is suggested to be close to the
clinical dose of ALN used to treat human osteoporosis11. Higher
doses of bisphosphonates may be beneﬁcial to both cartilage and
bone in OA; however the effect of continuous suppression of bone
turnover after long-term use needs to be determined. Supra
physiological doses of ALN and risedronate have shown to suppress
bone turnover by 90e95% in the vertebrae and increase micro-
damage accumulation in beagles33.
In our study, ALN did not have a signiﬁcant effect on osteophyte
formation, even though early ALN treatment seemed to slow down
osteophyte formation, which was not fully mineralised (Fig. 5).
Another pre-clinical study reported that ALN did not have a statis-
tically signiﬁcant effect on osteophyte score12. A few pre-clinical
studies have shown that ALN can inhibit osteophyte formation
however, in those studiesALN treatmentwas initiatedpre-emptively
or high dose of ALN was used11,13,34,35. In a clinical trial, Neogi et al.
showed that ALN reduced the progression of spinal osteophytes in
OA10. However, the spinal radiographic changes in that study were
subtle and may not have a major clinical relevance36.
OA is characterised by painful joints. In our study the rats
injected with low-dose MIA showed signiﬁcant decrease in HLWB
up to day 7, and pre-emptive ALN treatment signiﬁcantly prevented
the decrease in HLWB. Increased bone turnover and subchondral
bone pathology observed at 2 weeks in the OA group rats
coincide with decreased HLWB. In the MIA rat model, the iodoa-
cetate injection causes early phase neuropathy, which could be the
cause of pain37. Moreover, subchondral bone structural pathology
has been shown to be associated with knee pain in OA9,38. Carbone
et al. reported that ALN treatment decreased subchondral bone
attrition and reduced knee joint pain in postmenopausal women
with OA9. Risedronate has also been shown to non-signiﬁcantly
improve OA joint pain score from baseline7.
In the present study, the prevention of subchondral bone pa-
thology by ALN treatment could have resulted in alleviation of
weight-bearing deﬁcits in the low-dose MIA-induced OA rats. It is
also possible that the direct analgesic property of ALN could have
caused the alleviation of weight-bearing deﬁcits found in those
rats. Our observation for HLWB in the pre-emptive ALN group is
consistent with a recent study in which pre-emptive treatment
with zoledronic acid signiﬁcantly and dose-dependently reversed
weight-bearing deﬁcits in a high-doseMIA ratmodel16. A limitation
of our study is that wewere unable to follow early and delayed ALN
treatment effects on HLWB, as it became increasingly difﬁcult to ﬁt
the growing rats in the incapacitance tester. This would have given
additional information regarding ALN efﬁcacy on chronic pain.
Pre-emptive ALN, early ALN and delayed ALN treatment signif-
icantly decreased bone turnover rate; however, ALN treatment did
not have any effect on cartilage turnover. Human OA has been
shown to be associated with increased levels of serum COMP, CTX-I
and CTX-II39,40. Hayami et al. reported similar effects of ALN (30 mg/
kg/week) on COMP, CTX-I and urine CTX-II in OA rats11. As
mentioned earlier, high doses of ALN may be required to see a
signiﬁcant effect on cartilage as shown by Hayami et al. using
240 mg/kg/week ALN11.
Another limitation of our study is that the follow-up of pre-
emptive and early ALN treatment until the advanced stages of OA
ismissing. A longer-term follow-up couldhave revealed a signiﬁcant
effect of ALN on cartilage and osteophyte formation as observed inother studies11,12. However, our study design allowed us to deter-
mine the effect of ALN treatment on histological changes in the
cartilage at early, intermediate, and advanced stages of OA.
Conclusions
Subchondral bone plays an important role in the pathophysi-
ology of OA and ALN prevented increased bone turnover and pre-
served the structural integrity of subchondral bone in experimental
OA. Our study indicates that the time point of treatment initiation is
crucial for treating OA and treating both the subchondral bone and
cartilage in OA would be clinically more beneﬁcial.
Authors’ contributions
GM designed and conducted all experiments, performed data
collection, statistical analysis, graphical presentation of the data
collected, and prepared themanuscript for submission. EP, IHP, NLF,
and JSK were involved in the experimental design, interpretation of
the data and preparation of the manuscript; JMH was involved in
serum COMP, CTX-I and CTX-II analysis and data interpretation; All
authors have participated in the preparation of the manuscript and
have approved the ﬁnal version.
Funding source
GM is the recipient of Endeavour postgraduate scholarship from the
Australian Government, Department of Education, Employment,
and Workplace Relations (DEEWR). This study was supported in
part by funding from SA Pathology, Adelaide, Australia.
Conﬂicts of interest
The authors declare that they have no conﬂicts of interest.
Acknowledgements
The authors thank Dr Allan Rofe for kindly providing theMIA, Dr
Dorota Gancarz for assistance with the animal model, Ms Lena
Truong for assistance with animal dissection, Mrs Helen Tsangari
for preparing the resin sections (histology), the Institute of Medical
and Veterinary Science (IMVS) animal care facility staff, and Ade-
laide Microscopy staff.
Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.joca.2013.06.020.
References
1. Buckwalter JA, Saltzman C, Brown T. The impact of osteoar-
thritis: implications for research. Clin Orthop Relat Res 2004:
S6eS15.
2. Radin EL, Rose RM. Role of subchondral bone in the initiation
and progression of cartilage damage. Clin Orthop Relat Res
1986:34e40.
3. Bailey AJ, Mansell JP, Sims TJ, Banse X. Biochemical and me-
chanical properties of subchondral bone in osteoarthritis.
Biorheology 2004;41:349e58.
4. Burr DB. Anatomy and physiology of the mineralized tissues:
role in the pathogenesis of osteoarthrosis. Osteoarthritis
Cartilage 2004;12(Suppl A):S20e30.
5. Cohen SB. An update on bisphosphonates. Curr Rheumatol Rep
2004;6:59e65.
6. Buckland-Wright JC, Messent EA, Bingham 3rd CO, Ward RJ,
Tonkin C. A 2 yr longitudinal radiographic study examining the
G. Mohan et al. / Osteoarthritis and Cartilage 21 (2013) 1595e16041604effect of a bisphosphonate (risedronate) upon subchondral
bone loss in osteoarthritic knee patients. Rheumatology (Ox-
ford) 2007;46:257e64.
7. Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P,
Cline GA, Beary JF, et al. Effect of risedronate on joint structure
and symptoms of knee osteoarthritis: results of the BRISK
randomized, controlled trial [ISRCTN01928173]. Arthritis Res
Ther 2005;7:R625e33.
8. Bingham 3rd CO, Buckland-Wright JC, Garnero P, Cohen SB,
Dougados M, Adami S, et al. Risedronate decreases biochemical
markers of cartilage degradation but does not decrease
symptoms or slow radiographic progression in patients with
medial compartment osteoarthritis of the knee: results of the
two-year multinational knee osteoarthritis structural arthritis
study. Arthritis Rheum 2006;54:3494e507.
9. Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D,
et al. The relationship of antiresorptive drug use to structural
ﬁndings and symptoms of knee osteoarthritis. Arthritis Rheum
2004;50:3516e25.
10. Neogi T, Nevitt MC, Ensrud KE, Bauer D, Felson DT. The effect
of alendronate on progression of spinal osteophytes and disc-
space narrowing. Ann Rheum Dis 2008;67:1427e30.
11. Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A,
Destefano J, et al. The role of subchondral bone remodeling in
osteoarthritis: reduction of cartilage degeneration and pre-
vention of osteophyte formation by alendronate in the rat
anterior cruciate ligament transection model. Arthritis Rheum
2004;50:1193e206.
12. Shirai T, Kobayashi M, Nishitani K, Satake T, Kuroki H,
Nakagawa Y, et al. Chondroprotective effect of alendronate in a
rabbit model of osteoarthritis. J Orthop Res 2011;29:1572e7.
13. Zhang L, Hu H, Tian F, Song H, Zhang Y. Enhancement of
subchondral bone quality by alendronate administration for
the reduction of cartilage degeneration in the early phase of
experimental osteoarthritis. Clin Exp Med 2011;11:235e43.
14. Zhu S, ChenK, Lan Y, ZhangN, Jiang R, Hu J. Alendronate protects
against articular cartilage erosion by inhibiting subchondral
bone loss in ovariectomized rats. Bone 2013;53:340e9.
15. Mohan G, Perilli E, Kuliwaba JS, Humphries JM, Parkinson IH,
Fazzalari NL. Application of in vivo micro-computed tomogra-
phy in the temporal characterisation of subchondral bone ar-
chitecture in a ratmodel of low-dosemonosodium iodoacetate-
induced osteoarthritis. Arthritis Res Ther 2011;13:R210.
16. Strassle BW, Mark L, Leventhal L, Piesla MJ, Jian Li X,
Kennedy JD, et al. Inhibition of osteoclasts prevents cartilage
loss and pain in a rat model of degenerative joint disease.
Osteoarthritis Cartilage 2010;18:1319e28.
17. Compston J. Bone quality: what is it and how is it measured?
Arq Bras Endocrinol Metabol 2006;50:579e85.
18. Dempster DW. The contribution of trabecular architecture to
cancellous bone quality. J Bone Miner Res 2000;15:20e3.
19. Perilli E, Le V, Ma B, Salmon P, Reynolds K, Fazzalari NL.
Detecting early bone changes using in vivo micro-CT in
ovariectomized, zoledronic acid-treated, and sham-operated
rats. Osteoporos Int 2010;21:1371e82.
20. Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE,
Juneau PL, et al. Weight bearing as a measure of disease pro-
gression and efﬁcacy of anti-inﬂammatory compounds in a
model of monosodium iodoacetate-induced osteoarthritis.
Osteoarthritis Cartilage 2003;11:821e30.
21. Pomonis JD, Boulet JM,Gottshall SL, Phillips S, Sellers R, BuntonT,
et al. Development andpharmacological characterization of a rat
model of osteoarthritis pain. Pain 2005;114:339e46.
22. Hayami T, Pickarski M, Zhuo Y, Wesolowski GA, Rodan GA,
Duong le T. Characterization of articular cartilage andsubchondral bone changes in the rat anterior cruciate ligament
transection and meniscectomized models of osteoarthritis.
Bone 2006;38:234e43.
23. Pritzker KP, Gay S, Jimenez SA, Ostergaard K, Pelletier JP,
Revell PA, et al. Osteoarthritis cartilage histopathology:
grading and staging. Osteoarthritis Cartilage 2006;14:13e29.
24. Frost HM. Bone Histomorphometry: Analysis of Trabecular
Bone Dynamics. Florida: CRC Press, Inc.; 1983109e31.
25. Holm S. A simple sequentially rejective multiple test proce-
dure. Scand J Stat 1979;6:65e70.
26. Bobinac D, Spanjol J, Zoricic S, Maric I. Changes in articular
cartilage and subchondral bone histomorphometry in osteo-
arthritic knee joints in humans. Bone 2003;32:284e90.
27. ChappardC,PeyrinF, BonnassieA, LemineurG,Brunet-Imbault B,
Lespessailles E, et al. Subchondral bone micro-architectural al-
terations in osteoarthritis: a synchrotron micro-computed to-
mography study. Osteoarthritis Cartilage 2006;14:215e23.
28. Fazzalari NL, Parkinson IH. Femoral trabecular bone of osteo-
arthritic and normal subjects in an age and sex matched group.
Osteoarthritis Cartilage 1998;6:377e82.
29. Botter SM, van Osch GJ, Waarsing JH, Day JS, Verhaar JA,
Pols HA, et al. Quantiﬁcation of subchondral bone changes in a
murine osteoarthritis model using micro-CT. Biorheology
2006;43:379e88.
30. Ding M, Danielsen CC, Hvid I. Age-related three-dimensional
microarchitectural adaptations of subchondral bone tissues in
guineapigprimaryosteoarthrosis.CalcifTissue Int2006;78:113e22.
31. Lahm A, Kreuz PC, Oberst M, Haberstroh J, Uhl M, Maier D. Sub-
chondral and trabecularbone remodeling in canine experimental
osteoarthritis. Arch Orthop Trauma Surg 2006;126:582e7.
32. Brouwers JE, Lambers FM, Gasser JA, van Rietbergen B,
Huiskes R. Bone degeneration and recovery after early and late
bisphosphonate treatment of ovariectomized Wistar rats
assessed by in vivo micro-computed tomography. Calcif Tissue
Int 2008;82:202e11.
33. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC,
Burr DB. Effects of suppressed bone turnover by bisphosphonates
on microdamage accumulation and biomechanical properties in
clinically relevant skeletal sites inbeagles.Bone2001;28:524e31.
34. Jones MD, Tran CW, Li G, Maksymowych WP, Zernicke RF,
Doschak MR. In vivo microfocal computed tomography and
micro-magnetic resonance imaging evaluation of antiresorptive
and antiinﬂammatory drugs as preventive treatments of osteo-
arthritis in the rat. Arthritis Rheum 2010;62:2726e35.
35. Panahifar A, Maksymowych WP, Doschak MR. Potential
mechanism of alendronate inhibition of osteophyte formation
in the rat model of post-traumatic osteoarthritis: evaluation of
elemental strontium as a molecular tracer of bone formation.
Osteoarthritis Cartilage 2012;20:694e702.
36. Saag KG. Bisphosphonates for osteoarthritis prevention: “Holy
Grail” or not? Ann Rheum Dis 2008;67:1358e9.
37. Ivanavicius SP, Ball AD, Heapy CG, Westwood FR, Murray F,
Read SJ. Structural pathology in a rodent model of osteoar-
thritis is associated with neuropathic pain: increased expres-
sion of ATF-3 and pharmacological characterisation. Pain
2007;128:272e82.
38. Felson DT, Chaisson CE, Hill CL, Totterman SM, Gale ME,
Skinner KM, et al. The association of bone marrow lesions with
pain in knee osteoarthritis. Ann Intern Med 2001;134:541e9.
39. Abramson S, Krasnokutsky S. Biomarkers in osteoarthritis. Bull
NYU Hosp Jt Dis 2006;64:77e81.
40. Bettica P, Cline G, Hart DJ, Meyer J, Spector TD. Evidence for
increased bone resorption in patients with progressive knee
osteoarthritis: longitudinal results from the Chingford study.
Arthritis Rheum 2002;46:3178e84.
